Biogen Inc.
BIIB
Rang in Aktien
#704
Biogen Inc. is a leading biotechnology firm dedicated to the discovery,... Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Aktienkurs
$233.91
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$34.56B
Veränderung (1 Tag)
-0.61%
Veränderung (1 Jahr)
63.57%
Land
US
Handel Biogen Inc. (BIIB)
Kategorie
Healthcare
Operative Marge für Biogen Inc. (BIIB)
Operative Marge zum October 2026 TTM: 12.79%
Laut den neuesten Finanzberichten und dem Aktienkurs von Biogen Inc. beträgt die aktuelle operative Marge (TTM) 12.79%. Am Ende des Jahres 2024 lag die operative Marge bei 25.74%.
Historie der operativen Marge von Biogen Inc. von 2000 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 12.79% | -33.18% |
| 2025 | 19.14% | -25.64% |
| 2024 | 25.74% | 20.73% |
| 2023 | 21.32% | -25.25% |
| 2022 | 28.52% | 10.24% |
| 2021 | 25.87% | -23.55% |
| 2020 | 33.84% | -30.91% |
| 2019 | 48.98% | 11.90% |
| 2018 | 43.77% | 0.53% |
| 2017 | 43.54% | -3.22% |
| 2016 | 44.99% | -0.99% |
| 2015 | 45.44% | 36.99% |
| 2014 | 33.17% | -22.73% |
| 2013 | 42.93% | 27.62% |
| 2012 | 33.64% | -1.52% |
| 2011 | 34.16% | 138.55% |
| 2010 | 14.32% | -51.61% |
| 2009 | 29.59% | -0.10% |
| 2008 | 29.62% | -2.47% |
| 2007 | 30.37% | 29.23% |
| 2006 | 23.50% | 70.66% |
| 2005 | 13.77% | 406.25% |
| 2004 | 2.72% | -102.12% |
| 2003 | -128.05% | -787.70% |
| 2002 | 18.62% | -46.06% |
| 2001 | 34.52% | -2.60% |
| 2000 | 35.44% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 49.72% | -96.11% |
US
|
|
| 25.70% | -97.99% |
US
|
|
| 29.32% | -97.71% |
US
|
|
| 26.59% | -97.92% |
CH
|
|
| 16.65% | -98.70% |
US
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.